UnitedHealth Group is recovering from the enormous difficulties it faced in 2025. Remember that in that year, the company underestimated the cost of serving its customers and therefore did not price its policies appropriately, resulting in a significant decrease in the company's profitability and free cash flow .
Parkev Tatevosian, CFA on $UNH
Parkev Tatevosian, CFA has discussed $UNH in 2 videos since 2026-09-24. The latest, on 2026-11-11, was bullish.
2026-11-11Bullish
“Is it Too Late to Buy UnitedHealth Stock? | UNH Stock Analysis”
AI summary · UNH remains a buying opportunity: it is recovering from 2025 cost mispricing, long-term EPS growth estimates have rebounded to over 14.2% within management's 13-16% target, and high costs persist, with market exits and price increases reducing customers. At a forward P/E of 17, below pre-2025 levels and near long-term EPS growth, and with a DCF value of $532 versus $396 now, it looks undervalued; risk-reward is worthwhile though no stock is risk-free.
2026-09-24Bullish
“Is UnitedHealth Stock an Undervalued Stock to Buy Right Now? | UNH Stock Analysis”
AI summary · UNH is a buy; management's margin recovery and raised FCF estimates support ~40% upside in 12-18 months.
2025 was a very bad year for UnitedHealth, as the company's management team underestimated the cost of customer service. At the end of the year and the beginning of 2026, the management team made several adjustments to comply with current conditions.
As analysts, we were expecting certain results as a result of those adjustments. The results turned out to be better than expected. Today, I have raised my estimates for the company's free cash flow to adapt to these better conditions.